Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

We recently published a list of 10 Best Growth Stocks to Invest in for the Next 10 Years. In this article, we are going to ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

Crispr Therapeutics (CRSP), and Sarepta Therapeutics (SRPT) shares are lower in relation to a gene therapy death ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Beam Therapeutics in a research report issued on Wednesday, March 12th. Cantor Fitzgerald analyst ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

Citi raised the firm’s price target on Beam Therapeutics (BEAM) to $64 from $56 and keeps a Buy rating on the shares. With positive BEAM-302 ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...